Cost-effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: An Economic Evaluation

Simple item page
atmire.migration.oldid5425
dc.contributor.advisorClement, Fiona
dc.contributor.authorZhang, Ziyu
dc.contributor.committeememberMcBrien, Kerry
dc.contributor.committeememberSpackman, Eldon
dc.date.accessioned2017-04-13T20:12:30Z
dc.date.available2017-04-13T20:12:30Z
dc.date.issued2017
dc.date.submitted2017en
dc.description.abstractFamilial hypercholesterolemia is an autosomal inherited genetic disorder characterized by high levels of low-density lipoprotein cholesterol circulating in the bloodstream. If left untreated, this condition can substantially increase cardiovascular risk, lead to the rapid development of premature coronary artery disease, or cause sudden cardiac death. Despite the high risks associated with familial hypercholesterolemia, a considerable number of these individuals are unable to achieve adequate reductions in low-density lipoprotein cholesterol levels with conventional lipid lowering therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are emerging pharmacological treatments for managing patients with these conditions. Therefore, the goal of this thesis is to assess the cost-effectiveness of PCSK9 inhibitors for the treatment of elevated low-density lipoprotein cholesterol in individuals with familial hypercholesterolemia.en_US
dc.identifier.citationZhang, Z. (2017). Cost-effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: An Economic Evaluation (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/25475en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/25475
dc.identifier.urihttp://hdl.handle.net/11023/3697
dc.language.isoeng
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgaryen
dc.publisher.placeCalgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectHealth Care Management
dc.subjectPublic Health
dc.subject.otherHealth economics
dc.subject.otherCost-effectiveness
dc.subject.otherCost-utility analysis
dc.subject.otherFamilial hypercholesterolemia
dc.subject.otherLow-density lipoprotein cholesterol
dc.titleCost-effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: An Economic Evaluation
dc.typemaster thesis
thesis.degree.disciplineCommunity Health Sciences
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameMaster of Science (MSc)
ucalgary.item.requestcopytrue
Files
Collections
Open Theses and Dissertations